93 related articles for article (PubMed ID: 25417967)
1. Prevention of hepatitis C virus infection and spread in human liver chimeric mice by an anti-CD81 monoclonal antibody.
Ji C; Liu Y; Pamulapati C; Bohini S; Fertig G; Schraeml M; Rubas W; Brandt M; Ries S; Ma H; Klumpp K
Hepatology; 2015 Apr; 61(4):1136-44. PubMed ID: 25417967
[TBL] [Abstract][Full Text] [Related]
2. Anti-CD81 antibodies can prevent a hepatitis C virus infection in vivo.
Meuleman P; Hesselgesser J; Paulson M; Vanwolleghem T; Desombere I; Reiser H; Leroux-Roels G
Hepatology; 2008 Dec; 48(6):1761-8. PubMed ID: 19030166
[TBL] [Abstract][Full Text] [Related]
3. A human monoclonal antibody targeting scavenger receptor class B type I precludes hepatitis C virus infection and viral spread in vitro and in vivo.
Meuleman P; Catanese MT; Verhoye L; Desombere I; Farhoudi A; Jones CT; Sheahan T; Grzyb K; Cortese R; Rice CM; Leroux-Roels G; Nicosia A
Hepatology; 2012 Feb; 55(2):364-72. PubMed ID: 21953761
[TBL] [Abstract][Full Text] [Related]
4. Alirocumab, a Therapeutic Human Antibody to PCSK9, Does Not Affect CD81 Levels or Hepatitis C Virus Entry and Replication into Hepatocytes.
Ramanathan A; Gusarova V; Stahl N; Gurnett-Bander A; Kyratsous CA
PLoS One; 2016; 11(4):e0154498. PubMed ID: 27115873
[TBL] [Abstract][Full Text] [Related]
5. Monoclonal antibodies against extracellular domains of claudin-1 block hepatitis C virus infection in a mouse model.
Fukasawa M; Nagase S; Shirasago Y; Iida M; Yamashita M; Endo K; Yagi K; Suzuki T; Wakita T; Hanada K; Kuniyasu H; Kondoh M
J Virol; 2015 May; 89(9):4866-79. PubMed ID: 25673725
[TBL] [Abstract][Full Text] [Related]
6. Monoclonal Antibodies against Occludin Completely Prevented Hepatitis C Virus Infection in a Mouse Model.
Shimizu Y; Shirasago Y; Kondoh M; Suzuki T; Wakita T; Hanada K; Yagi K; Fukasawa M
J Virol; 2018 Apr; 92(8):. PubMed ID: 29437969
[TBL] [Abstract][Full Text] [Related]
7. A novel monoclonal anti-CD81 antibody produced by genetic immunization efficiently inhibits Hepatitis C virus cell-cell transmission.
Fofana I; Xiao F; Thumann C; Turek M; Zona L; Tawar RG; Grunert F; Thompson J; Zeisel MB; Baumert TF
PLoS One; 2013; 8(5):e64221. PubMed ID: 23704981
[TBL] [Abstract][Full Text] [Related]
8. PCSK9 impedes hepatitis C virus infection in vitro and modulates liver CD81 expression.
Labonté P; Begley S; Guévin C; Asselin MC; Nassoury N; Mayer G; Prat A; Seidah NG
Hepatology; 2009 Jul; 50(1):17-24. PubMed ID: 19489072
[TBL] [Abstract][Full Text] [Related]
9. Association of anti-E1E2 antibodies with spontaneous recovery or sustained viral response to therapy in patients infected with hepatitis C virus.
Ndongo N; Berthillon P; Pradat P; Vieux C; Bordes I; Berby F; Maynard M; Zoulim F; Trépo C; Petit MA
Hepatology; 2010 Nov; 52(5):1531-42. PubMed ID: 20890942
[TBL] [Abstract][Full Text] [Related]
10. Neutralizing antibodies induced by cell culture-derived hepatitis C virus protect against infection in mice.
Akazawa D; Moriyama M; Yokokawa H; Omi N; Watanabe N; Date T; Morikawa K; Aizaki H; Ishii K; Kato T; Mochizuki H; Nakamura N; Wakita T
Gastroenterology; 2013 Aug; 145(2):447-55.e1-4. PubMed ID: 23673355
[TBL] [Abstract][Full Text] [Related]
11. Primary hepatocytes of Tupaia belangeri as a potential model for hepatitis C virus infection.
Zhao X; Tang ZY; Klumpp B; Wolff-Vorbeck G; Barth H; Levy S; von Weizsäcker F; Blum HE; Baumert TF
J Clin Invest; 2002 Jan; 109(2):221-32. PubMed ID: 11805134
[TBL] [Abstract][Full Text] [Related]
12. Practical evaluation of a mouse with chimeric human liver model for hepatitis C virus infection using an NS3-4A protease inhibitor.
Kamiya N; Iwao E; Hiraga N; Tsuge M; Imamura M; Takahashi S; Miyoshi S; Tateno C; Yoshizato K; Chayama K
J Gen Virol; 2010 Jul; 91(Pt 7):1668-77. PubMed ID: 20164258
[TBL] [Abstract][Full Text] [Related]
13. Hepatitis C virus infection in mouse hepatoma cells co-expressing human CD81 and Sip-L.
Yeh CT; Lai HY; Yeh YJ; Cheng JC
Biochem Biophys Res Commun; 2008 Jul; 372(1):157-61. PubMed ID: 18474223
[TBL] [Abstract][Full Text] [Related]
14. Scavenger receptor class B type I is a key host factor for hepatitis C virus infection required for an entry step closely linked to CD81.
Zeisel MB; Koutsoudakis G; Schnober EK; Haberstroh A; Blum HE; Cosset FL; Wakita T; Jaeck D; Doffoel M; Royer C; Soulier E; Schvoerer E; Schuster C; Stoll-Keller F; Bartenschlager R; Pietschmann T; Barth H; Baumert TF
Hepatology; 2007 Dec; 46(6):1722-31. PubMed ID: 18000990
[TBL] [Abstract][Full Text] [Related]
15. Prevention of hepatitis C virus infection using a broad cross-neutralizing monoclonal antibody (AR4A) and epigallocatechin gallate.
O'Shea D; Law J; Egli A; Douglas D; Lund G; Forester S; Lambert J; Law M; Burton DR; Tyrrell DL; Houghton M; Humar A; Kneteman N
Liver Transpl; 2016 Mar; 22(3):324-32. PubMed ID: 26389583
[TBL] [Abstract][Full Text] [Related]
16. Impact of single nucleotide polymorphisms in the essential HCV entry factor CD81 on HCV infectivity and neutralization.
Deest M; Westhaus S; Steinmann E; Manns MP; von Hahn T; Ciesek S
Antiviral Res; 2014 Jan; 101():37-44. PubMed ID: 24211330
[TBL] [Abstract][Full Text] [Related]
17. Discovery of anti-claudin-1 antibodies as candidate therapeutics against hepatitis C virus.
Yamashita M; Iida M; Tada M; Shirasago Y; Fukasawa M; Nagase S; Watari A; Ishii-Watabe A; Yagi K; Kondoh M
J Pharmacol Exp Ther; 2015 Apr; 353(1):112-8. PubMed ID: 25628391
[TBL] [Abstract][Full Text] [Related]
18. Hepatic cell-to-cell transmission of small silencing RNA can extend the therapeutic reach of RNA interference (RNAi).
Pan Q; Ramakrishnaiah V; Henry S; Fouraschen S; de Ruiter PE; Kwekkeboom J; Tilanus HW; Janssen HL; van der Laan LJ
Gut; 2012 Sep; 61(9):1330-9. PubMed ID: 22198713
[TBL] [Abstract][Full Text] [Related]
19. Anti-CD81 but not anti-SR-BI blocks Plasmodium falciparum liver infection in a humanized mouse model.
Foquet L; Hermsen CC; Verhoye L; van Gemert GJ; Cortese R; Nicosia A; Sauerwein RW; Leroux-Roels G; Meuleman P
J Antimicrob Chemother; 2015; 70(6):1784-7. PubMed ID: 25656410
[TBL] [Abstract][Full Text] [Related]
20. Preclinical evaluation of two human anti-hepatitis B virus (HBV) monoclonal antibodies in the HBV-trimera mouse model and in HBV chronic carrier chimpanzees.
Eren R; Ilan E; Nussbaum O; Lubin I; Terkieltaub D; Arazi Y; Ben-Moshe O; Kitchinzky A; Berr S; Gopher J; Zauberman A; Galun E; Shouval D; Daudi N; Eid A; Jurim O; Magnius LO; Hammas B; Reisner Y; Dagan S
Hepatology; 2000 Sep; 32(3):588-96. PubMed ID: 10960454
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
